Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 701–769 of 769
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.references
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.07
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.06
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.03
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.04
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.02
Conclusion and Future Perspectives
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.08
Circulating biochemical signatures of neurodegeneration in Alzheimer’s disease
Eliazer, G. R., & Kandasamy, M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.06.004
Advances in the Diagnosis and Management of Alzheimer’s Disease
Joshi, P., Tsai, P., Alix, A., & Gopalakrishna, G. (2026) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2026.05.004
Research Advances in Diagnostic Methods for Prevalent Neurological Diseases
Lv, M., Sun, X., & Wang, X. (2026) · Biosensors · doi:10.3390/bios16070368
Dunlop, S. R., Lincoln, S., Peng, Z., Graff‐Radford, N. R., Lachner, C., Day, G. S., Tranovich, J. F., Reichard, R. R., Dickson, D. W., Petersen, R. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.01.735558
Nan, N., & Tian, L. (2026) · Journal of Applied Statistics · doi:10.1080/02664763.2026.2703182
Sun, S., Yang, B., Chen, S., Huang, Q., Zhang, Y., Li, N., Peng, Q., Tam, K. Y., Wang, H., & Ying, Z. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113365
Yang, F., Gong, T., Li, X., Jiang, B., Yuan, R., & Xiang, Y. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119221
Brain aging clocks: From methodological advances to cellular mechanisms
Suk, K. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113260
Estradiol and memory circuitry in the postmenopause: Modification by APOE4Preprint
Schroeder, R. A., Thurston, R. C., Wu, M., Aizenstein, H. J., Karikari, T. K., Kamboh, M. I., Cohen, A. D., & Maki, P. M. (2026) · Research Square · doi:10.21203/rs.3.rs-10057599/v1
Self-citationProkopiou, P. C., Egroo, M. V., Riphagen, J. M., Baillet, M., Ashton, N. J., Janelidze, S., Sperling, R. A., Johnson, K. A., Blennow, K., Hansson, O., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71703
Self-citationMapping Amyloid-PET Uptake in the White Matter in Alzheimer’s DiseasePreprint
Harput, E., Boccalini, C., Scheffler, M., Lövblad, K., Ashton, N. J., Zetterberg, H., Hansson, O., Lalive, H. M., Lathuilière, A., Frisoni, G. B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10277565/v1
Self-citationConcordance between plasma biomarkers of phosphorylated tau and tau-PET: A narrative review
van Houwelingen, A., Vernooij, M. W., Vermeiren, M. R., Ossenkoppele, R., van de Giessen, E., Seelaar, H., & Neitzel, J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261468708
Boutajangout, A., Osorio, R. S., Masurkar, A. V., Debure, L., Ghuman, M., Ahmed, W., Pirraglia, E., Vedvyas, A., Links, J., Vega, B., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70419
Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics
Vigneswaran, S., Verberk, I. M. W., Boonkamp, L., Veld, L. I. ‘., Simmelink, M. J. A., Antwi‐Berko, D., van Unen, L., Rousset, R. Z., Claessen, T., Zwan, M. D., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.28864
Coig, R., Jain, L., Khrestian, M., Tuason, E. D., Rao, S. M., Pillai, J. A., Leverenz, J. B., & Bekris, L. M. (2026) · medRxiv · doi:10.64898/2026.08.12.26360207
Alburhan, M., Munthir, A., & ALDOORİ, B. (2026) · Libyan Journal of Applied and Contemporary Sciences · doi:10.64943/ljacs.2026.010203
Czech, J., Weyland, C. S., Neumann, M., Drzezga, A. E., & Schulz, J. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-13040-2_6
Novel cell markers with altered expression in brain aging and Alzheimer's disease: A review
Alobu, E. J., Uchewa, O. O., & Ibegbu, A. O. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.08.010
Biomarker Discovery in Neurodegenerative Disorders
Dubois, N., Novak, O., & Schmidt, M. (2023) · Excerpta Medica Archives Journal: Transaction A · doi:10.5281/zenodo.19613195
Ragolia, L. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00552-y
Bergamo, G., Fernandes, M., Maio, S., Albanesi, G., Antonucci, M., Barbaro, I. Y. A. N., Cirillo, F., Fernando, L., Amicucci, G., Centonze, D., et al. (2026) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2026.112237
Guvatova, Z. G., Kobelyatskaya, A. A., Gorbunov, A., Pudova, E. A., & Moskalev, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177580
Silent clues in blood: Proteomic approach for Alzheimer’s disease
da Silva, A. R. V., da Conceição, R. S. V., Medeiros, C. M. D. S., Sousa, M. D. S., de Jesus, J. R., & Júnior, C. A. L. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.009
Mulligan, M. D., Wang, R., Yang, Q., Beiser, A., Maillard, P., Satizábal, C. L., Ghosh, S., Tanner, J. A., Johnson, K. A., DeCarli, C. S., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261480733
Mastrangelo, A., Baiardi, S., Ruggeri, E., Bentivenga, G. M., Vargiu, C. M., Mammana, A., Sbriccoli, M., Polischi, B., Carlà, B., Capellari, S., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03076-5
Elecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology
Ritchie, C. W., Hortsch, S., Quijano‐Rubio, C., Menzel, P., Kirste, I., Caley, D., Burke, A. D., Rowe, C. C., Suárez‐Calvet, M., Aarsland, D., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70439
Li, Z., Li, Y., Liu, R., Zhu, Y. M., Wang, R., Lu, K. P., & Zhou, X. Z. (2026) · Cells · doi:10.3390/cells15181650
BIOMARCADORES SANGUÍNEOS NO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER: UMA REVISÃO INTEGRATIVA
Crüz, K. P., dos Santos, K. V. R., Júnior, A. V. D. P., dos Santos, W. P., Nascimento, G. M., Medeiros, A. C. M., Mendonça, A. F. R., Neto, L. T. P., Schlote, K., & Gutzeit, E. M. (2026) · Revista Tópicos · doi:10.70773/revistatopicos/789452327
Luo, Y. R., Zheng, L., & Shin, S. (2026) · Advances in clinical chemistry · doi:10.1016/bs.acc.2026.09.001
Dynamic contributions of astrocytes in Alzheimer’s disease
Guo, F., Li, T., & He, X. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.116032
Aerospace stressors and brain health in military aviators: a glymphatic–neurovascular framework
Ramirez, J., Marraffino, V. N., Anirud, U. A., & Rhind, S. G. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1953796
The use of blood biomarkers to understand responses to lecanemab treatment
Ryan, N. S. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(26)00359-5
Ho, B., & Yang, Y.-H. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2734618
Utilidad del diagnóstico precoz de enfermedad de Alzheimer con biomarcadores en plasma
Lamoth, E. B., Larrarte, J. P. M., Abreu, S. M. P., Hernández, E. F., & Rojas, Y. G. M. (2025) · Revista Cubana de Reumatología: RCuR
Wang, S., Zhang, J., 孙绍军, Xiao, R., 张志镒, & Yao, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1886781
Zhang, X. T., Murphy, M., Riordan, H., Wang, K., Esquivel, R., Xu, W., Zhang, X., Gong, X., Sun, Y., & Lu, Y. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2740372
Rewriting Phosphorylation Codes: Toward Signal-State Editing with PhosTACs
Ke, D.-T., Chang, W.-C., Chen, Y.-Y., & Chen, P. (2026) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases4040029
Babygirija, R., Illiano, J., Sonsalla, M. M., Zhu, G., Jabbarpour, C. R., Mathew, T., Molkentin, T., Peterson, M., Winder, C., Nair, A. R. K., et al. (2026) · Aging Cell · doi:10.1111/acel.70767
Advancing early detection of Alzheimer's disease: from established biomarkers to future innovations
Qu, L., Wang, Y., Ren, L., Zhang, C., Guo, Z., Zhang, L., Pang, X., & Sha, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117537
Future Directions in Neurochemistry and Brain Disorders
Tripathi, P. N., Gangwar, M., Singh, N. K., Verma, V. C., Singh, J. K., & Marwaha, J. (2026) · Royal Society of Chemistry eBooks · doi:10.1039/9781837071395-00337
Vidyanti, A. N., Prawiroharjo, P., Syafrita, Y., Prodjohardjono, A., Rahmadini, A., Hidayatun, P. I. R., Rahman, R., Divina, E., Permata, R. I., Tazkia, A. A., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261497299
Ho, S. G., Shen, Z., Lewis, A., Patel, M., Zheng, A., Proscino, G., Ho, T., Wang, J., Albert, M., & Moghekar, A. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70524
Gao, P., Tan, H., Li, G., Liang, J., Yang, M., Xu, D., Wang, Q., Liang, S., Xiao, Z., Zheng, X., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11017150/v1
Perneczky, R., Schöll, M., Rauchmann, B., & Hofmann, A. (2026) · Neuron · doi:10.1016/j.neuron.2026.09.006
Self-citationYukawa, K., Muraoka, S., Grace, S., Cafaro, L., Adachi, J., Ikezu, T., & Ikezu, S. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101683
APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI
Chu, K.-Y. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09435-0
Marginal Analysis of Clustered Interval‐Censored Competing Risks Data With Informative Cluster Size
Wang, X., Wang, P., & Song, X. (2026) · Statistics in Medicine · doi:10.1002/sim.70792
Fan, D., Zhai, W., Zhang, Q., Li, J., Wang, Y., & Sun, L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261499707
Luo, D., Lv, X., Mu, H., Tao, X., Chen, H., Cui, Z., & Gao, P. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1997082
González‐Ortiz, F., Kirsebom, B., Santos, C., Arslan, B., Gundersen, J. K., Kvartsberg, H., Sävman, K., Turton, M., Harrison, P., Gleerup, H. S., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag413
Self-citationAbdolmaleki, M., Gaynor, L. S., Liu, D., Hohman, T. J., Gifford, K. A., Zetterberg, H., Jefferson, A. L., & Bolton, C. J. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70565
Self-citationLabonte, J., Miner, A. E., Groh, J. R., Montoliu‐Gaya, L., Tripodis, Y., Aparicio, H. J., Turk, K. W., Budson, A. E., Farrer, L. A., Goldstein, L. E., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14232-y
Self-citationChen, X., Yang, Y., Liao, Y., Chen, L., Cheng, L., Su, C., Shi, X., Chen, J., Lin, Z., & Hong, G. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.119400
Comparative Evaluation of SNAP25 in Cerebrospinal Fluid and Plasma Across Three CohortsPreprint
Sauer, M., Machado, L. S., Rocker, C., Goossens, J., Grötschel, L., Janelidze, S., Rahmouni, N., Ribaldi, F., Therriault, J., Trudel, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11320091/v1
Self-citationOyovwi, M. O., Rume, R. A., & Ben‐Azu, B. (2026) · Journal of Molecular Pathology · doi:10.3390/jmp7040040
Xie, X., Peng, L., Zhu, T., Jiang, J., Huang, Y., Gan, L., Zhou, L., Chen, X., & Chen, C. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2026.141243
Snellman, A., Ekblad, L. L., Koivumäki, M., Lindgrén, N., Tuisku, J., Perälä, M., Kallio, L., Lehtonen, R., Saunavaara, V., Saunavaara, J., et al. (2022) · doi:10.3389/fneur.2022.826423.s001
Self-citationWu, L., Arvai, S., Wang, S.-H. J., Liu, A. J., & Xu, B. (2024) · doi:10.3389/fnmol.2023.1288930.s001
Wang, Y.-L., Chen, J., Du, Z.-L., Weng, H., Zhang, Y., Li, R., Jia, Z., Sun, M., Jiang, J., Wang, F.-Z., et al. (2021) · doi:10.3389/fneur.2021.695696.s004
Cao, T. H. M., Le, A. P. H., Tran, T. T., Huynh, V. K., Pham, B. H., Le, T. M., Nguyen, Q. L., Tran, T. C., Tong, T. M., Than, T. H. N., et al. (2023) · doi:10.3389/fnmol.2023.1308610.s002
Early Prediction of Alzheimer’s Disease by Using Blood-Based Biomarkers: A Comprehensive Review
Rahman, A., & Islam, M. D. (2026) · Journal of Bangladesh College of Physicians and Surgeons · doi:10.3329/jbcps.v44i4.94415
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.